Granulocyte transfusion therapy 2006: The comeback kid?

The Comeback Kid?

Balloon angioplasty revolutionized coronary revascularization; however, elastic recoil and restenosis caused by cellular proliferation are major drawbacks of angioplasty. Intracoronary stenting, which could tackle dissections and eliminate elastic recoil, became the next mode of intervention but was limited by stent thrombosis and increased neointimal hyperplasia, leading to in-stent restenosis...

The comeback kid: TYSABRI now FDA approved for Crohn disease.

The Journal of Clinical Investigation http://www.jci.org Volume 118 Number 3 March 2008 825 The comeback kid: TYSABRI now FDA approved for Crohn disease The US FDA recently approved the monoclonal antibody TYSABRI (natalizumab) for use in the treatment of adults with moderately to severely active Crohn disease (CD) who do not respond to, or do not tolerate, conventional therapies for CD and inh...

Granulocyte transfusion therapy: randomization after all?

A practical guide to granulocyte transfusion therapy.

A major development for the supportive care of patients with bone marrow suppression has been the recent introduction of techniques for collecting granulocytes from suitable donors. There is increasing awareness in this country that granulocyte transfusion for infected neutropenic patients is now a practical possibility, and the demand for granulocytes from those centres able to provide this se...

Granulocyte transfusion therapy of experimental Pseudomonas pneumonia.

Pseudomonas pneumonia was produced in dogs with radiation-induced leukopenia. Treatment of this infection with either gentamicin alone or gentamicin plus daily granulocyte transfusion was compared in a randomized controlled trail. The dogs receiving granulocytes plus gentamicin survived significantly longer than those treated with gentamicin alone (P < 0.05). The Pseudomonas immunotype which wa...